Novocure Stock Buy Hold or Sell Recommendation
| NVCR Stock | USD 20.04 0.35 1.78% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Novocure is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Novocure given historical horizon and risk tolerance towards Novocure. When Macroaxis issues a 'buy' or 'sell' recommendation for Novocure, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Novocure Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide. Note, we conduct extensive research on individual companies such as Novocure and provide practical buy, sell, or hold advice based on investors' constraints. Novocure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Novocure |
Execute Novocure Buy or Sell Advice
The Novocure recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novocure. Macroaxis does not own or have any residual interests in Novocure or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novocure's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Novocure Trading Alerts and Improvement Suggestions
| Novocure had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 509.34 M. Net Loss for the year was (207.04 M) with profit before overhead, payroll, taxes, and interest of 423.58 M. | |
| Novocure currently holds about 948.52 M in cash with (73.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06. | |
| Novocure has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: FDA Approves Novocures Innovative HFE Transducer Arrays for Use With Optune Gio for Glioblastoma |
Novocure Returns Distribution Density
The distribution of Novocure's historical returns is an attempt to chart the uncertainty of Novocure's future price movements. The chart of the probability distribution of Novocure daily returns describes the distribution of returns around its average expected value. We use Novocure price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novocure returns is essential to provide solid investment advice for Novocure.
| Mean Return | 0.12 | Value At Risk | -6.48 | Potential Upside | 8.08 | Standard Deviation | 4.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novocure historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novocure Stock Institutional Investors
The Novocure's institutional investors refer to entities that pool money to purchase Novocure's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.3 M | Millennium Management Llc | 2024-06-30 | 1.2 M | Voloridge Investment Management, Llc | 2024-09-30 | 1 M | Federated Hermes Inc | 2024-09-30 | 997.4 K | Northern Trust Corp | 2024-09-30 | 923.5 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 908 K | Frontier Capital Management Co Inc | 2024-09-30 | 871.4 K | Balyasny Asset Management Llc | 2024-09-30 | 839.2 K | Fmr Inc | 2024-09-30 | 16.2 M | Blackrock Inc | 2024-06-30 | 12.1 M |
Novocure Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.2M) | (2.9M) | 2.5M | (4.3M) | (8.9M) | (8.5M) | |
| Investments | (41.2M) | (457.9M) | (120.7M) | (140.0M) | (42.4M) | (44.5M) | |
| Change In Cash | 36.7M | 66.8M | (36.6M) | (93.8M) | 126.7M | 133.1M | |
| Net Borrowings | (31K) | 408.4M | (26K) | (28K) | (32.2K) | (30.6K) | |
| Free Cash Flow | 16.1M | 84.2M | 58.6M | 9.4M | (100.4M) | (95.4M) | |
| Depreciation | 8.5M | 9.2M | 10.3M | 10.6M | 11.0M | 7.8M | |
| Other Non Cash Items | (2.2M) | 3.3M | 3.0M | (6.1M) | (22.4M) | (21.3M) | |
| Capital Expenditures | 10.5M | 15.0M | 24.2M | 21.4M | 27.1M | 14.6M | |
| Net Income | (7.2M) | 19.8M | (58.4M) | (92.5M) | (207.0M) | (196.7M) | |
| End Period Cash Flow | 179.4M | 246.2M | 209.6M | 115.8M | 242.6M | 166.8M | |
| Change To Netincome | 51.9M | 75.5M | 101.8M | 104.7M | 120.4M | 126.4M | |
| Change Receivables | (36.5M) | (30.4M) | 5.3M | 2.5M | 2.9M | 3.1M |
Novocure Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novocure or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novocure's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novocure stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.19 | |
β | Beta against Dow Jones | 2.39 | |
σ | Overall volatility | 4.17 | |
Ir | Information ratio | -0.0036 |
Novocure Volatility Alert
Novocure exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novocure's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novocure's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novocure Fundamentals Vs Peers
Comparing Novocure's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novocure's direct or indirect competition across all of the common fundamentals between Novocure and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novocure or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novocure's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novocure to competition |
| Fundamentals | Novocure | Peer Average |
| Return On Equity | -0.4 | -0.31 |
| Return On Asset | -0.0793 | -0.14 |
| Profit Margin | (0.26) % | (1.27) % |
| Operating Margin | (0.21) % | (5.51) % |
| Current Valuation | 1.85 B | 16.62 B |
| Shares Outstanding | 108.2 M | 571.82 M |
| Shares Owned By Insiders | 9.25 % | 10.09 % |
| Shares Owned By Institutions | 86.64 % | 39.21 % |
| Number Of Shares Shorted | 5.67 M | 4.71 M |
| Price To Earning | 721.15 X | 28.72 X |
| Price To Book | 5.91 X | 9.51 X |
| Price To Sales | 3.69 X | 11.42 X |
| Revenue | 509.34 M | 9.43 B |
| Gross Profit | 423.58 M | 27.38 B |
| EBITDA | (175.87 M) | 3.9 B |
| Net Income | (207.04 M) | 570.98 M |
| Cash And Equivalents | 948.52 M | 2.7 B |
| Cash Per Share | 9.06 X | 5.01 X |
| Total Debt | 596.24 M | 5.32 B |
| Debt To Equity | 1.31 % | 48.70 % |
| Current Ratio | 8.08 X | 2.16 X |
| Book Value Per Share | 3.34 X | 1.93 K |
| Cash Flow From Operations | (73.34 M) | 971.22 M |
| Short Ratio | 4.31 X | 4.00 X |
| Earnings Per Share | (1.39) X | 3.12 X |
| Price To Earnings To Growth | (0.47) X | 4.89 X |
| Target Price | 26.71 | |
| Number Of Employees | 1.45 K | 18.84 K |
| Beta | 0.71 | -0.15 |
| Market Capitalization | 2.13 B | 19.03 B |
| Total Asset | 1.15 B | 29.47 B |
| Retained Earnings | (985.5 M) | 9.33 B |
| Working Capital | 855.29 M | 1.48 B |
Note: Disposition of tradable shares by Mukund Paravasthu of Novocure at 16.6858 subject to Rule 16b-3 [view details]
Novocure Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novocure . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Novocure Buy or Sell Advice
When is the right time to buy or sell Novocure? Buying financial instruments such as Novocure Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novocure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Services Thematic Idea Now
Services
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.